Loading
PDBj
メニューPDBj@FacebookPDBj@TwitterPDBj@YouTubewwPDB FoundationwwPDB
RCSB PDBPDBeBMRBAdv. SearchSearch help

6WKM

Fab Fragment of Anti-human LAG3 antibody (22D2)

6WKM の概要
エントリーDOI10.2210/pdb6wkm/pdb
分子名称22D2 Fab Heavy Chain, 22D2 Fab Light Chain (3 entities in total)
機能のキーワードanti human lag3, immune system
由来する生物種Mus musculus
詳細
タンパク質・核酸の鎖数2
化学式量合計48977.37
構造登録者
Agnihotri, P.,Mishra, A.K.,Mariuzza, R.A. (登録日: 2020-04-16, 公開日: 2021-04-21, 最終更新日: 2024-10-23)
主引用文献Mishra, A.K.,Shahid, S.,Karade, S.S.,Agnihotri, P.,Kolesnikov, A.,Hasan, S.S.,Mariuzza, R.A.
CryoEM structure of a therapeutic antibody (favezelimab) bound to human LAG3 determined using a bivalent Fab as fiducial marker.
Structure, 2023
Cited by
PubMed Abstract: Lymphocyte activation gene 3 protein (LAG3) is an inhibitory receptor that is upregulated on exhausted T cells in tumors. LAG3 is a major target for cancer immunotherapy with many anti-LAG3 antibodies in clinical trials. However, there is no structural information on the epitopes recognized by these antibodies. We determined the single-particle cryoEM structure of a therapeutic antibody (favezelimab) bound to LAG3 to 3.5 Å resolution, revealing that favezelimab targets the LAG3-binding site for MHC class II, its canonical ligand. The small size of the complex between the conventional (monovalent) Fab of favezelimab and LAG3 (∼100 kDa) presented a challenge for cryoEM. Accordingly, we engineered a bivalent version of Fab favezelimab that doubled the size of the Fab-LAG3 complex and conferred a highly identifiable shape to the complex that facilitated particle selection and orientation for image processing. This study establishes bivalent Fabs as new fiducial markers for cryoEM analysis of small proteins.
PubMed: 37619561
DOI: 10.1016/j.str.2023.07.013
主引用文献が同じPDBエントリー
実験手法
X-RAY DIFFRACTION (2.1 Å)
構造検証レポート
Validation report summary of 6wkm
検証レポート(詳細版)ダウンロードをダウンロード

226707

件を2024-10-30に公開中

PDB statisticsPDBj update infoContact PDBjnumon